scholarly journals Menstrual cycle and gynecologic pathology in menstrual-related migraine

2021 ◽  
Vol 13 (4) ◽  
pp. 12-17
Author(s):  
E. A. Kiryanova ◽  
G. R. Tabeeva
Keyword(s):  
Menstrual Cycle ◽  
Cycle Length ◽  
Hormonal Contraception ◽  
Reproductive Age ◽  
Patient Evaluation ◽  
Women Of Reproductive Age ◽  
Endometrial Polyps ◽  
Leading Role ◽  
Prospective Comparative Study ◽  
Group 2

Migraine is the first most frequent cause of disability among women of reproductive age globally, and up to 60% of patients note the association of headache attacks with menstruation.Objective: to determine the features of menstrual cycle and gynecologic pathology in women with menstrual-related migraine (MRM).Patients and methods. A prospective comparative study included 69 women of reproductive age with a migraine diagnosis who did not receive hormonal contraception. Depending on the association of migraine attacks with menstruation (according to headache diaries), the patients were divided into two groups: the 1st group consisted of 44 patients with MRM; group 2 — 25 patients with non-menstrual migraine (without the association of attacks with menstruation).Results and discussion. Patients with MRM had heavier menstrual bleeding, longer menstruations (more than six days), abnormal menstrual cycle length and regularity, dysmenorrhea. In addition, the obtained data indicate a comorbid estrogen-associated gynecological pathology (endometriosis, adenomyosis, endometrial polyps, myoma) in MRM.Conclusion. Presumably, the hypothalamic-pituitary-ovarian axis dysfunction plays the leading role in the MRM. It presents with menstrual cycle abnormalities and increased presence of estrogen-associated gynecological pathology, which should be considered during patient evaluation and suggesting recommendations.

Features of the cervix uteri in women of reproductive age with endometrial polyps and micropolyps

2016 ◽  
pp. 108-111
Author(s):  
T.F. Tatarchuk ◽  
◽  
D.G. German ◽  
Keyword(s):  
Reproductive Age ◽  
Cervix Uteri ◽  
Control Group ◽  
Women Of Reproductive Age ◽  
Endometrial Polyps ◽  
Group Iii ◽  
Aggressive Form ◽  
Group I ◽  
Group Ii ◽  
Control Group Group

The article presents the comparative analysis of the state of the cervix in women with endometrial polyps and micropolyps. Patients and methods. The study involved 130 patients aged 18-35 years: 70 patients with endometrial polyps (group I), 30 patients with micropolyps (group II) and 30 patients of the control group (group III). Results. According to the anamnesis of women in the I group were significantly more frequent diseases of the cervix, which corrected physical surgery methods, in particular cryodestruction. In group II, the representatives of these indicators were similar to healthy. Normal colposcopic picture met significantly less frequently in patients and I, and II group. The differences in the incidence of HPV high oncogenic risk in all groups were not statistically significant. Conclusion. Destructive methods used in the detection of any changes in the cervix are often overly aggressive, form scars and contributing to inflamaciones process. In the chain of events leading to the formation of PE, cervical pathology and its correction can take the basic place. Key words: endometrial polyp, micropolyps, chronic endometritis, uterine cervix, colposcopy.

scholarly journals Possible impact of variations in some Cytokine levels during menstrual cycle in women of reproductive age infected with Pulmonary Tuberculosis at Nnewi, Nigeria'

2018 ◽  
Vol 08 (02) ◽  
Author(s):  
Nkiruka Rose Ukibe ◽  
Solomon Nwabueze Ukibe ◽  
Emmanuel Ikechukwu Onwubuya ◽  
Chinedum Charles Onyenekwe ◽  
Ifeoma Nwamaka Monago ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Pulmonary Tuberculosis ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Cytokine Levels

scholarly journals The Impact of the COVID-19 Pandemic on Women’s Reproductive Health

2021 ◽  
Vol 12 ◽  
Author(s):  
Phelan Niamh ◽  
Lucy Ann Behan ◽  
Lisa Owens
Keyword(s):  
Reproductive Health ◽  
Cycle Length ◽  
Home Schooling ◽  
Hormonal Contraception ◽  
Median Number ◽  
Reproductive Age ◽  
Poor Sleep ◽  
Women’S Reproductive Health ◽  
Women's Reproductive Health ◽  
The Impact

BackgroundThe COVID-19 pandemic has profoundly affected the lives of the global population. It is known that periods of stress and psychological distress can affect women’s menstrual cycles. We therefore performed an observational study of women’s reproductive health over the course of the pandemic thus far.Materials and MethodsAn anonymous digital survey was shared by the authors via social media in September 2020. All women of reproductive age were invited to complete the survey.Results1031 women completed the survey. Mean age was 36.7 ± 6.6 years (range, 15–54). 693/70% reported recording their cycles using an app or diary. 233/23% were using hormonal contraception. 441/46% reported a change in their menstrual cycle since the beginning of the pandemic. 483/53% reported worsening premenstrual symptoms, 100/18% reported new menorrhagia (p = 0.003) and 173/30% new dysmenorrhea (p < 0.0001) compared to before the pandemic. 72/9% reported missed periods who not previously missed periods (p = 0.003) and the median number of missed periods was 2 (1–3). 17/21% of those who “occasionally” missed periods pre-pandemic missed periods “often” during pandemic. 467/45% reported a reduced libido. There was no change in the median cycle length (28 days) or days of bleeding (5) but there was a wider variability of cycle length (p = 0.01) and a 1 day median decrease in the minimum (p < 0.0001) and maximum (p = 0.009) cycle length. Women reported a median 2 kg increase in self-reported weight and a 30-min increase in median weekly exercise. 517/50% of women stated that their diet was worse and 232/23% that it was better than before the pandemic. 407/40% reported working more and 169/16% were working less. Women related a significant increase in low mood (p < 0.0001), poor appetite (p < 0.0001), binge eating (p < 0.0001), poor concentration (p < 0.0001), anxiety (p < 0.0001), poor sleep (p < 0.0001), loneliness (p < 0.0001) and excess alcohol use (p < 0.0001). Specific stressors reported included work stress (499/48%), difficulty accessing healthcare (254/25%), change in financial (201/19%) situation, difficulties with home schooling (191/19%) or childcare (99/10%), family or partner conflict (170/16%), family illness or bereavement (156/15%).ConclusionsThe COVID-19 pandemic has significantly impacted the reproductive health of women. The long term health implications of this are yet to be determined and future studies should address this.

Prognostic value of levels of specific autoantibodies in patients of reproductive age with endometrial polyps

2021 ◽  
pp. 33-36
Author(s):  
L. V. Tkachenko ◽  
N. I. Sviridova ◽  
I. A. Gritsenko ◽  
S. N. Maksimov
Keyword(s):  
Blood Serum ◽  
Prognostic Value ◽  
Reference Range ◽  
Relative Content ◽  
Reproductive Age ◽  
Enzyme Linked Immunosorbent Assay ◽  
Women Of Reproductive Age ◽  
Endometrial Polyps ◽  
Double Stranded Dna

The problem of endometrial polyps in women of reproductive age is one of the urgent problems of modern gynecology. The detection rate of PE according to the data of domestic and foreign scientists reaches 25–35%, and therefore they occupy a leading place in the structure of intrauterine pathology.The aim. To study the levels of specific autoantibodies (to double-stranded DNA; to TrM‑03 antigens and collagen) and to assess their prognostic value for the risk of PE formation and recurrence in patients of reproductive age.Materials and methods. Examination of 86 patients aged 18 to 45 years (average age was 34.1 ± 6.3 years), admitted for hysteroscopy, hysteroresection of PE. Study of the relative content of specific autoantibodies to double-stranded DNA; to TrM‑03 antigens and collagen in blood serum was carried out by the method of enzyme-linked immunosorbent assay using specialized reagent kits (ELI-P-Complex).Results. In the course of this study, it was found that in the overwhelming majority of cases (65.1%) PEs were manifested by various types of AMC. All patients with PE were diagnosed with a significant decrease in the level of autoantibodies to double-stranded DNA, which is a marker of apoptosis processes, as well as a statistically significant decrease in the levels of autoantibodies to platelet antigens TrM‑03. The profile of deviations in the level of autoantibodies to TrM‑03 from the reference range in the area of negative values correlated with an increase in the average level of autoantibodies to collagen.Conclusions. Determination of the levels of auto-ATs to double-stranded DNA in serum can be used as a marker for predicting the recurrent course of PE. Determination of the levels of auto-ATs to platelet antigens TrM‑03 and to collagen in blood serum can be used as markers for the development of AMC by the type of BMC or a combination of BMC and BMC in patients with endometrial polyps.

scholarly journals Plasma Volume, Hydration and Nutritional Biomarker Concentrations Across the Menstrual Cycle (P24-052-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sixtus Aguree ◽  
Hilary Bethancourt ◽  
Leigh Taylor ◽  
Asher Yoel Rosinger ◽  
Lacy M Alexander ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Plasma Volume ◽  
Plasma Osmolality ◽  
Reproductive Age ◽  
Magnesium Concentration ◽  
Women Of Reproductive Age ◽  
Blood Draw ◽  
Healthy Women ◽  
Markers Of Inflammation ◽  
Concentration Changes

Abstract Objectives To examine changes in plasma volume, hydration, and micronutrient concentrations across the menstrual cycle among healthy women of reproductive age. Methods Healthy women aged 18 to 44 years were studied longitudinally across a single menstrual cycle (n = 35). Women made three visits (v1, v2, and v3) to the study center around cycle days 2, 12 and 21 (adjusted for individual cycle length) representing early follicular, late follicular and midluteal phases, respectively. At each visit, blood samples were collected before and after injection of indocyanine green (ICG). ICG in plasma was measured with a spectrophotometer within 2 hours of blood draw, to estimate plasma volume. Urine specific gravity (USG) was measured with a hand-held refractometer; urine and plasma osmolality were measured using freezing point depression osmometry. Serum ferritin was measured by ELISA; serum concentrations for 5 minerals were measured by inductively coupled plasma mass spectrometry. A mixed-effects model was used to examine changes in plasma volume and biomarker concentrations across the menstrual cycle; plasma volume and biomarker associations were tested with Spearman's correlation. Results Participants had a mean (SD) BMI of 21.6 (1.9) kg/m2. Plasma volume showed a non-significant decrease of 122 mL from v1 to v2 (P = 0.165; Table 1) and remained stable from v2 to v3 (P = 0.900). However, plasma osmolality decreased throughout the cycle from v1 to v3 (P < 0.001). Urine osmolality fell slightly from v1 to v2 (P = 0.214) followed by a significant rise from v2 to v3 (P = 0.026) but USG was constant across the cycle. From v1 to v3, serum magnesium concentration declined by 4.5% (P = 0.001); zinc had a similar decline that did not reach statistical significance (P = 0.057). Mean copper, calcium, manganese, ferritin, and hemoglobin concentrations did not change across the cycle (all P > 0.05). Adjusting for markers of inflammation (α1-acid glycoprotein and C-reactive protein) and plasma volume did not affect biomarker concentration changes. Plasma volume was not correlated with nutritional biomarkers at any timepoint (all P > 0.05, Table 2). Conclusions Concentrations of micronutrients were not related to plasma volume. Some hydration and micronutrient biomarkers changed across the menstrual cycle, which could have implications for the timing of measurements in women of reproductive age. Funding Sources The Pennsylvania State University. Supporting Tables, Images and/or Graphs

scholarly journals Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study

BMJ ◽  
2018 ◽  
pp. k3609 ◽  
Author(s):  
Lisa Iversen ◽  
Shona Fielding ◽  
Øjvind Lidegaard ◽  
Lina S Mørch ◽  
Charlotte W Skovlund ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Relative Risk ◽  
Hormonal Contraception ◽  
Reproductive Age ◽  
Hormonal Contraceptives ◽  
Ovarian Cancer Risk ◽  
Women Of Reproductive Age ◽  
Ovarian Cancers ◽  
Study Population ◽  
Combined Hormonal Contraceptives

AbstractObjectivesTo investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer.DesignProspective, nationwide cohort study.SettingDenmark, 1995-2014.ParticipantsAll women aged 15-49 years during 1995-2014 were eligible. Women were excluded if they immigrated after 1995, had cancer (except non-melanoma skin cancer), had venous thrombosis, or were treated for infertility before entry (final study population included 1 879 227 women). Women were categorised as never users (no record of being dispensed hormonal contraception), current or recent users (≤1 year after stopping use), or former users (>1 year after stopping use) of different hormonal contraceptives.Main outcome measuresPoisson regression was used to calculate relative risk of ovarian cancer among users of any contemporary combined hormonal contraceptives and by progestogen type in combined preparations and all progestogen-only products, including non-oral preparations. Separate analyses examined women followed up to their first contraception type switch and those with full contraceptive histories. Duration, time since last use, and tumour histology were examined and the population prevented fraction were calculated.ResultsDuring 21.4 million person years, 1249 incident ovarian cancers occurred. Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13 344 531 person years. Never users had 771 ovarian cancers during 8 150 250 person years. Compared with never users, reduced risks of ovarian cancer occurred with current or recent use and former use of any hormonal contraception (relative risk 0.58 (95% confidence interval 0.49 to 0.68) and 0.77 (0.66 to 0.91), respectively). Relative risks among current or recent users decreased with increasing duration (from 0.82 (0.59 to 1.12) with ≤1 year use to 0.26 (0.16 to 0.43) with >10 years’ use; P<0.001 for trend). Similar results were achieved among women followed up to their first switch in contraceptive type. Little evidence of major differences in risk estimates by tumour type or progestogen content of combined oral contraceptives was seen. Use of progestogen-only products were not associated with ovarian cancer risk. Among ever users of hormonal contraception, the reduction in the age standardised absolute rate of ovarian cancer was 3.2 per 100 000 person years. Based on the relative risk for the never use versus ever use categories of hormonal contraception (0.66), the population prevented fraction was estimated to be 21%—that is, use of hormonal contraception prevented 21% of ovarian cancers in the study population.ConclusionsUse of contemporary combined hormonal contraceptives is associated with a reduction in ovarian cancer risk in women of reproductive age—an effect related to duration of use, which diminishes after stopping use. These data suggest no protective effect from progestogen-only products.

Sign in / Sign up

Export Citation Format

Share Document